Last reviewed · How we verify
Laboratorios Richmond S.A.C.I.F. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Treatment with nifedipine | Treatment with nifedipine | phase 3 | Calcium channel blocker | L-type calcium channels | Cardiovascular |
Therapeutic area mix
- Cardiovascular · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Addpharma Inc. · 1 shared drug class
- Ain Shams University · 1 shared drug class
- Bioprojet · 1 shared drug class
- Boryung Pharmaceutical Co., Ltd · 1 shared drug class
- Bristol-Myers Squibb · 1 shared drug class
- GlaxoSmithKline · 1 shared drug class
- Handok Inc. · 1 shared drug class
- · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Laboratorios Richmond S.A.C.I.F.:
- Laboratorios Richmond S.A.C.I.F. pipeline updates — RSS
- Laboratorios Richmond S.A.C.I.F. pipeline updates — Atom
- Laboratorios Richmond S.A.C.I.F. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Laboratorios Richmond S.A.C.I.F. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/laboratorios-richmond-s-a-c-i-f. Accessed 2026-05-17.